Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A.
Masato BingoKatsuyuki FukutakeKanae TogoLinghua XuJosé Maria Jimenez AlvirIan WinburnToshiyuki KarumoriPublished in: Drugs - real world outcomes (2024)
Prescribing of EHL products increased over the study and healthcare expenditures increased for patients who switched from SHL to EHL rFVIII products.